Navigation Links
Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer
Date:7/16/2009

Treatment safe in advanced disease but more study is needed, experts say

THURSDAY, July 16 (HealthDay News) -- The oral cancer drug sunitinib (Sutent) has shown promising results in advanced kidney cancer patients who have a poor prognosis, new research says.

Previous clinical trials showed that sunitinib was effective in patients with advanced kidney cancer, and the drug has been approved worldwide as a first- and second-line treatment for these patients, according to background information with the study. However, little is known about the drug's activity in advanced kidney cancer patients with poor prognosis, such as those whose cancer has spread to the brain, those with poor performance status, and the elderly.

The new study, published online and in the August print issue of The Lancet Oncology, included 4,564 poor-prognosis patients in 52 countries who were divided into four subgroups, including those with brain metastases, poor performance status, non-clear-cell renal cell carcinoma, and patients aged 65 and older.

All of the patients received 50 milligrams of sunitinib once daily, repeated in six-week cycles (four weeks on treatment followed by two weeks off treatment). The researchers assessed tumor response, toxicity, and adverse events at regular intervals.

The study authors reported that the median progression-free survival was 10.9 months, and overall survival was 18.4 months, which was an improvement over previous findings. In the four subgroups, the response rates were: brain metastases, 12 percent; non-clear-renal cell carcinoma, 11 percent; poor performance status, 9 percent; and elderly, 17 percent; with an overall objective response rate of 17 percent.

Overall, the study found that the drug can be given safely and is well-tolerated in all four subgroups. Diarrhea (44 percent) and fatigue (37 percent) were the most common treatment-related adverse events, the study authors noted.

In an article accompanying the study, experts added that "the safety and efficacy of sunitinib in an older population are confirmed and evidence shows that age alone should not be a deterrent from attempting therapy."

But "patients with brain metastases, non-clear-cell histology, and poor performance status benefit less from sunitinib, despite good drug tolerance, suggesting the need for prospective studies in these subpopulations," wrote Dr. Joaquim Bellmunt of Hospital del Mar in Barcelona, Spain, and the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and Dr. Toni K. Choueiri of Dana-Farber and Harvard.

"Thus, claiming sunitinib as a 'standard' in these subgroups remains controversial. An oncologist might not have access to such trials in practice, however, and based on available information the use of sunitinib may be justified in these subpopulations," they concluded.

More information

The U.S. National Cancer Institute has more about kidney cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, July 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In Colorado, Commercial Medical and Pharmacy Benefit Enrollment Down at State Level
2. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments
3. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
4. A Phase III Alzheimers Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
5. Regular moderate alcohol intake has cognitive benefits in older adults
6. Pinnacle Health Solutions Launches New Web Site, Making Affordable Health Care and Benefits Easy to Understand
7. Chief Medical Officer Joins Aon Consultings Health & Benefits Practice
8. First Annual Congressional Womens Softball Game to Benefit the Young Survival Coalition
9. Harvard Medical School Continues Education About Benefits of Probiotics
10. Omega-3s Benefit Heart Attack Survivors, Healthy Adults, Mothers and Infants
11. The Max Cure Foundation Announces Its First Charity Benefit: The Roar for a Cure Carnival to Be Held on Saturday, August 22, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology: